COMMUNIQUÉS West-GlobeNewswire
-
Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
26/11/2018 - 13:30 -
CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals
26/11/2018 - 13:25 -
Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
26/11/2018 - 13:05 -
Resonant Inc. Initiates $4 Million Stock Repurchase Program
26/11/2018 - 13:05 -
Form 8 (DD) - Shire plc
26/11/2018 - 13:00 -
Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1
26/11/2018 - 13:00 -
Repeat: Canopy Rivers Secures International Joint Venture Rights and Accelerates Development at PharmHouse
26/11/2018 - 13:00 -
Zafgen Provides Update on Investigational New Drug Application for ZGN-1061
26/11/2018 - 13:00 -
Aleafia Posts Record Revenue in Q3 2018, 36% Increase Over Previous Quarter
26/11/2018 - 13:00 -
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
26/11/2018 - 13:00 -
Aravive Announces Participation at Upcoming Investor Conference
26/11/2018 - 13:00 -
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
26/11/2018 - 12:30 -
Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China
26/11/2018 - 12:00 -
Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.
26/11/2018 - 12:00 -
Transactions under Novozymes’ stock buyback program
26/11/2018 - 10:07 -
Registration of the reduced quantity of shares in Nexstim Plc (the first phase)
26/11/2018 - 09:02 -
Latvijas Juras medicinas centrs JSC: interim report for the 9 months of 2018
26/11/2018 - 08:11 -
JSC Olainfarm Invites To Join Company’s Presentation At CEO Meets Investors Event In Riga
26/11/2018 - 08:02 -
Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)
26/11/2018 - 08:00
Pages